Research and Markets: Commercial Insight: Vaccines - Reaching Adulthood.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com) has announced the addition of Commercial Insight: Vaccines - Reaching Adulthood to their offering. Introduction The vaccine sector has historically been dominated by five key companies, which derived value from high volume sales or relatively cheap commodity vaccine products. However, recent years have seen the introduction of higher-value offerings, such as Wyeths Prevnar, and the involvement of a greater number of smaller vaccine players, changing the dynamics of this sector. Scope Historical sales analysis for total market and key vaccine sectors, including hepatitis B Hepatitis B Definition Hepatitis B is a potentially serious form of liver inflammation due to infection by the hepatitis B virus (HBV). It occurs in both rapidly developing (acute) and long-lasting (chronic) forms, and is one of the most common chronic , influenza influenza or flu, acute, highly contagious disease caused by a virus; formerly known as the grippe. There are three types of the virus, designated A, B, and C, but only types A and B cause more serious contagious infections. and pediatric pediatric /pe·di·at·ric/ (pe?de-at´rik) pertaining to the health of children. pe·di·at·ric adj. Of or relating to pediatrics. vaccine fields Detailed hepatitis B, influenza and pediatric vaccine profiles, including recommendations for capitalizing on key strengths and opportunities Forecast mature market annual vaccine sales for current and future disease targets, including hepatitis B, influenza, DTaP and hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. In-depth analysis of the options for product improvement, including novel delivery routes, new adjuvants and alternative antigenic components Highlights The vaccine market continues to represent the fastest growing ID sector with historical growth reaching 26% (CAGR CAGR See: Compound Annual Growth Rate 1999-2003). However, this has been driven by product improvements as opposed to new antigen coverage and, despite the increasing involvement of less influential players, significant barriers maintain the trend towards consolidation. US initiatives aimed at increasing vaccine coverage in adults (READII and VFARH) and late-stage R&D activities (e.g. Adacel, Boostrix, Menactra and HPV vaccines Human papillomavirus (HPV) vaccine is a vaccine that targets certain sexually transmitted strains of human papillomavirus associated with the development of cervical cancer and genital warts.[1] Two HPV vaccines are currently on the market: Gardasil and Cervarix. ) reflect the high unmet need in the adult sector. As a result of these factors, products aimed at the 11-65 group will drive future market expansion. Historically, the benefits associated with vaccine life-cycle management (LCM (Liquid Crystal Monitor) A flat panel display that uses the liquid crystal (LCD) technology. See flat panel display. ) have been restricted by a lack of competition, reduced threat from generics players and limited options for such activities. However, as a result of the introduction of high-value vaccine products, the importance of effective LCM will become more apparent. This report is designed to: Benchmark R&D vaccines against current market leaders and assess opportunities for market penetration Noun 1. market penetration - the extent to which a product is recognized and bought by customers in a particular market penetration - the act of entering into or through something; "the penetration of upper management by women" Predict the future performance of current and future vaccine sectors, as defined by target disease and target patient group Identify options for product enhancement and develop strategies that will infer real competitive advantage to your existing and R&D vaccines For more information visit http://www.researchandmarkets.com/reports/c5430 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion